- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07644273
Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. (PELVICATHLE)
Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. Single-Center Randomized Controlled Stepped-Wedge Trial
A prevalence of urinary incontinence ranging from 5.7% to 80% has been observed in young nulliparous athletes during their activity.
The usual recommendations for managing adult women do not seem to be transferable.
Young nulliparous athletes need specific educational and behavioral interventions and an alternative to pelvic floor muscle strengthening.
A multimodal and multidimensional intervention for athletes and coaches combining specific pelvic health education and strengthening of lumbopelvic-abdominal stability appears to be an innovative and optimal solution for reducing the symptoms of urinary incontinence in young nulliparous women who participate in athletics.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Pascal EDOUARD, PHD
- Número de telefone: +33 (0)477127985
- E-mail: pascal.edouard@univ-st-etienne.fr
Estude backup de contato
- Nome: Céline PEURIERE, CDP
- Número de telefone: +33 (0)477120285
- E-mail: Celine.Peuriere@chu-st-etienne.fr
Locais de estudo
-
-
-
Saint-Etienne, França, 42055
- CHU de Saint-Etienne
-
Investigador principal:
- Pascal EDOUARD, PHD
-
Contato:
- Pascal EDOUARD, PHD
- Número de telefone: +33 (0)477127985
- E-mail: pascal.edouard@univ-st-etienne.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria :
- Female subject, nulliparous
- Member of an athletics club affiliated with the French Athletics Federation (FFA)
- At least 15 years old at the start of the study and belonging to the U16/U18/U20/U23 categories (born between January 1, 2005, and September 1, 2011)
- Having internet access
- Having access to a digital device (computer, tablet, mobile phone)
- Affiliated with or covered by a social security scheme
- Having freely given their express consent, as well as the express consent of both parents for minor participants
Exclusion Criteria :
- Any individual deprived of their liberty or subject to legal protection (guardianship, curatorship, or protective supervision).
- A pregnant woman, a woman who has been pregnant, or a woman planning a pregnancy within the last nine months.
- Any individual unable to understand the purpose and conditions of the study.
- Any individual unable to give their consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Control condition
Usual activities
|
Collection of data on routine activities
|
|
Experimental: Interventional condition
Combined pelvic health education and lumbar-pelvic-abdominal stability strengthening program.
|
The intervention will consist of participants: i) reviewing educational content (8 educational videos online) ii) participating in two in-person sessions at the athletics club and performing lumbar-pelvic-abdominal stability exercises iii) learning and implementing recommendations for empowering themselves in pelvic health management. iv) complete reports in 6 questionnaires during follow-up. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Urinary incontinence symptoms
Prazo: Week 1, 7, 13, 19, 25, 31
|
Severity of urinary incontinence symptoms as measured by the ICIQ-UI-SF score (International Consultation on Incontinence Questionnaire - Short Form for Urinary Incontinence).
Scores typically range from 0 to 21.
The higher the score, the more severe the urinary incontinence.
|
Week 1, 7, 13, 19, 25, 31
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The program's effects on the prevalence of urinary incontinence
Prazo: Week 1, 7, 13, 19, 25, 31
|
The program's effects on the prevalence of urinary incontinence will be measured using the ICIQ-UI-SF questionnaire, with a dichotomous interpretation of the score: 0 = continent, ≥1 = incontinent.
|
Week 1, 7, 13, 19, 25, 31
|
|
Effects of the intervention on athletes' knowledge of the pelvic-perineal region
Prazo: Week 1, 31
|
A questionnaire we have developed will measure the effects of the intervention on athletes' knowledge of the pelvic and perineal region.
It will consist of 10 questions.
This outcome will be assessed by comparing the mean number of correct answers (on a scale of 0 to 10) within and between groups.
|
Week 1, 31
|
|
The program's effects on associated pelvic and perineal symptoms
Prazo: Week 1, 31
|
The ODS-S questionnaires measure associated pelvic and perineal symptoms.
This criterion will be assessed by comparing the mean total scores (on a scale of 0 to 20) within and between groups.
|
Week 1, 31
|
|
The program's effects on urinary dysfunction.
Prazo: Week 1, 31
|
Section C of the LURN-SI29 questionnaire, which assesses urinary dysfunction.
This criterion will be evaluated by comparing the mean total scores (on a scale of 0 to 20) within and between groups.
|
Week 1, 31
|
|
Number of educational contents viewed
Prazo: Week 13, 19, 25
|
Measured by tracking content views at the end of the session.
|
Week 13, 19, 25
|
|
Practicing lower back, pelvic, and abdominal stability exercises
Prazo: Week 1, 7, 13, 19, 25, 31
|
Measured by collecting the frequency of implementation.
|
Week 1, 7, 13, 19, 25, 31
|
|
The dose-response effect related to adherence
Prazo: Week 1, 7, 13, 19, 25, 31
|
Assessed by measuring the effects on the ICIQ-UI-SF score based on the frequency of exercise implementation.
Scores typically range from 0 to 21.
The higher the score, the more severe the urinary incontinence.
|
Week 1, 7, 13, 19, 25, 31
|
|
Program satisfaction
Prazo: Week 31
|
Assessed using a questionnaire.
This criterion will be expressed as the average of the total scores for the satisfaction and recommendation questions (on a scale of 0 to 10).
A score of "10" indicates high satisfaction and a strong recommendation.
|
Week 31
|
|
Trends in Top Athletic Performance
Prazo: Week 1, 7, 13, 19, 25, 31
|
Measured by the best performance (time/distance) in the most common track and field event. Time is measured in seconds and minutes. Distance is measured in meters. |
Week 1, 7, 13, 19, 25, 31
|
|
Number of educational contents viewed by coaches
Prazo: Week 13, 19, 25
|
Measured by tracking content views at the end of the session
|
Week 13, 19, 25
|
|
Coaches' level of knowledge regarding the pelvic-perineal region
Prazo: Week 1, 31
|
Assessed using a 10-question questionnaire.
This criterion will be expressed through an intra-group and inter-group comparison of the average number of correct answers (on a scale of 0 to 10).
|
Week 1, 31
|
|
Practicing lumbar-pelvic-abdominal stability exercises
Prazo: Week 1, 7, 13, 19, 25, 31
|
Measured by collecting the frequency as specified in a questionnaire
|
Week 1, 7, 13, 19, 25, 31
|
|
Coaches' satisfaction with the program
Prazo: Week 31
|
Assessed using a questionnaire.
This criterion will be expressed as the average of the total scores for the satisfaction and recommendation questions (on a scale of 0 to 10).
A score of "10" indicates high satisfaction and a strong recommendation.
|
Week 31
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Pascal EDOUARD, PHD, CHU de Saint-Etienne
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Incontinencia urinaria
Outros números de identificação do estudo
- 26CH163
- ANSM (Outro identificador: 2024-A02435-42)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .